A prospective, interventional, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of Bacillus coagulans LBSC in the treatment of acute diarrhea with abdominal discomfort
- 99 Downloads
Increasing resistance towards antibiotics has augmented the use of probiotics for the treatment of diarrhea and associated symptoms. Probiotics are active microorganisms which exert some health benefits when consumed in the right amount. This randomized, double-blind, placebo-controlled clinical trial was conducted on 60 “intention to treat” subjects to evaluate the safety and efficacy of probiotic preparation Lactic Acid Bacillus (LAB containing active ingredient Bacillus coagulans strain LBSC) for the treatment of acute diarrhea with abdominal discomfort.
The Test-A arm (n = 30) was on B. coagulans LBSC [2 billion/g] and Placebo-B arm (n = 30) was on the carrier. The primary outcomes were the time to last unformed stool (TTLUS), number of unformed stools, change in severity of abdominal pain, time to complete resolution of abdominal discomfort, complete remission of diarrhea, and quality of life (QoL). The secondary outcomes were physical examination and vitals, hematological analysis, and assessment of reported adverse events (AEs) or serious adverse events (SAEs).
Trial data showed that the LAB was well-tolerated by participants at the dose provided. The LAB was effective in recovering from acute diarrhea with abdominal pain and discomforts and exhibited improved cluster of QoL. No AEs or SAEs were reported during the trial.
It is evident that the test drug, i.e., LAB (B. coagulans strain LBSC) is safe and effective for improving the pathophysiological conditions related to acute diarrhea and abdominal discomfort evaluated through stage-II clinical trial.
KeywordsBacillus coagulans Diarrhea Abdominal pain Bristol stool scale Quality of life
Authors are grateful to Mr. V.L. Rathi, Mr. C.L. Rathi, Mr. Mukund Kabra, and Mr. Piyush Rathi at Advanced Enzyme Technologies Ltd. for their technical inputs and providing the laboratory facilities to carry out the study.
Author contribution statement
CM designed the study protocol, and monitored and prepared the manuscript. AKG reviewed the protocol and manuscript, and approved with technical inputs.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This study is conducted in compliance with the applicable ethical standards Harmonized Tripartite Guidelines for Good Clinical Practice (GCP), the relevant sections of Good Laboratory Practice (GLP), local laws and regulations, and the provisions of the Declaration of Helsinki. The EC Approval [Reference No.: RH/IEC/AP-002/2018 and Dated: 16/01/2018] and registration of the Clinical Trials Registry—India (CTRI) [Reference No.: CTRI/2018/01/011635 and Dated: 31/01/2018] were obtained prior to the clinical trial study.
- 1.World Health Organization (2018) The factsheet: antimicrobial resistance. http://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
- 2.World Health Organization (WHO) (2006) The treatment of diarrhea. A Manual for Physicians and Senior Health Workers WHO/ FCH/CAH/ 03.7Google Scholar
- 5.Johnston BC, Supina AL, Ospina M, Vohra S (2007) Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev (2):CD004827. https://doi.org/10.1002/14651858.CD004827.pub2
- 7.La Rosa M, Bottaro G, Gulino N, Gambuzza F, Di Forti F, Inì G, Tornambè E (2003) Prevention of antibiotic-associated diarrhea with Lactobacillus sporogens and fructo-oligosaccharides in children. A multicentric double-blind vs placebo study. Minerva Pediatr 55:447–452Google Scholar
- 9.Saneian H, Pourmoghaddas Z, Roohafza H, Gholamrezaei A (2015) Synbiotic containing Bacillus coagulans and fructo-oligosaccharides for functional abdominal pain in children. Gastroenterol Hepatol Bed Bench 8:56–65Google Scholar
- 10.World Medical Association Declaration of Helsinki (2000) Ethical principles for medical research involving human subjects. 52nd WMA general assembly. Scotland, EdinburghGoogle Scholar
- 11.International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for good clinical practice [E6(R1)], June 1996Google Scholar
- 12.Indian Council of Medical Research (ICMR) (2006) Ethical guidelines for biomedical research on human participants. New Delhi. http://www.cns.iisc.ac.in/wordpress/wpcontent/uploads/2017/01/ethical_guidelines.pdf. Accessed 2 Mar 2018
- 14.Food and Agriculture Organization (FAO) and World Health Organization (WHO) Expert Consultation (2001) Evaluation of health and nutritional properties of powder milk and live lactic acid bacteria. Food and Agriculture Organization of the United Nations and World Health Organization, CórdobaGoogle Scholar
- 15.European Food Safety Authority (2018) Update of the list of QPS-recommended biological agents intentionally added to food or feed as notified to EFSA 7: suitability of taxonomic units notified to EFSA until September 2017. EFSA panel on biological hazards (BIOHAZ). EFSA J 16:e05131Google Scholar
- 17.Sudha MR, Radkar N, Maurya A (2011) Effect of supplementation of probiotic Bacillus coagulans Unique IS-2 on hypercholesterolemia subjects: a clinical study. Int J Probiotics Prebiotics 6:89–94Google Scholar
- 18.Ara K, Meguro S, Hase T, Tokimitsu I, Otsuji K, Kawai S, Ito S, Iino H (2002) Effect of spore-bearing lactic acid-forming bacteria (Bacillus coagulans SANK 70258) administration on the intestinal environment, defecation frequency, fecal characteristics and dermal characteristics in humans and rats. Microb Ecol Health Dis 14:4–13CrossRefGoogle Scholar
- 20.Sudha RM, Bhonagiri S (2012) Efficacy of Bacillus coagulans strain Unique IS-2 in the treatment of patients with acute diarrhea. Int J Probiotics Prebiotics 7:33–37Google Scholar
- 21.Majeed M, Nagabhushanam K, Natarajan S, Sivakumar A, Ali F, Pande A, Majeed S, Karri SK (2016) Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant irritable bowel syndrome: a double blind randomized placebo controlled pilot clinical study. Nutr J 15:21CrossRefGoogle Scholar
- 22.Stefano G, Licia P, Mona Abu Z, Jorge Amil D, Luigi Gobio C, Hans H, Sanja K, Karin M, Dusanka MT, Alexandra P, Jaime Salazar S, Bhupinder S, Hanna S, Zvi W (2000) Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastroenterol Nutr 30:54–60CrossRefGoogle Scholar
- 27.Carabotti M, Scirocco A, Maselli MA, Severia C (2015) The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol 28:203–209Google Scholar
- 31.Kirjavainen PV, EINezami HS, Salminen SJ, Ahokas JT, Wright PFA (1999) Effects of orally administered viable Lactobacillus rhamnosus GG and Propionibacterium freudenreichii subsp. shermanii JS on mouse lymphocyte proliferation. Clin Diagn Lab Immunol 6:799–802Google Scholar
- 32.Hungin APS, Mulligan C, Pot B, Whorwell P, Agreus L, Fracasso P, Lionis C, Mendive J, Foy JMP, Rubin G, Winchester C, Wit N (2013) Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice – an evidence based international guide. Aliment Pharmacol Ther 38:864–886CrossRefGoogle Scholar
- 39.Giannetti E, Maglione M, Alessandrella A, Strisciuglio C, Giovanni DD, Campanozzi A, Miele E, Staiano A (2017) A mixture of 3 bifidobacteria decreases abdominal pain and improves the quality of life in children with irritable bowel syndrome a multicenter, randomized, double-blind, placebo-controlled, crossover trial. J Clin Gastroenterol 51:e5–e10CrossRefGoogle Scholar
- 41.Kalman DS, Schwartz HI, Alvarez P, Feldman S, Pezzullo JC, Krieger DR (2009) A prospective, randomized, double-blind, placebo-controlled parallel-group dual site trial to evaluate the effects of a Bacillus coagulans-based product on functional intestinal gas symptoms. BMC Gastroenterol 9:85CrossRefGoogle Scholar
- 42.Lahiri K, Jadhav K, Gahlowt P, Najmuddin F (2015) Bacillus clausii as an adjuvant therapy in acute childhood diarrhea. IOSR J Dent Med Sci 14:74–76Google Scholar
- 47.Giralt J, Regadera JP, Verges R, Romero J, Fuente I, Biete A, Villoria J, Cobo JM, Guarner F (2008) Effects of probiotic Lactobacillus casei DN-114 001 in prevention of radiation-induced diarrhea: results from multicenter, randomized, placebo-controlled nutritional trial. Int J Radiat Oncol Biol Phys 71:1213–1219CrossRefGoogle Scholar
- 48.Lisa C, Gina B, Kathleen B, Autumn D, Beth M, Melanie O, Meghann S, Felicia V, Dawn W, Alison S, Jeffry K (2011) A randomized, double-blind, placebo-controlled pilot study of Lactobacillus reuteri ATCC 55730 for the prevention of antibiotic-associated diarrhea in hospitalized adults. J Clin Gastroenterol 45:785–789CrossRefGoogle Scholar
- 52.Majeed M, Nagabhushanam K, Natarajan S, Vaidyanathan P, Arumugam S, Karri SK (2017) Process for the therapeutic management of darrhea predominant irritable bowel syndrome using Bacillus coagulans SBC-37-01, MTCC 5856. Patent No. US 9,579,352 B2. https://patentimages.storage.googleapis.com/2e/73/cd/f9a8344c81e152/US9579352.pdf. Accessed 15 Dec 2017